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Abstract The cyclic guanosine-3P,5P-monophosphate (cGMP)
analogue, 8-bromo-cGMP (1 mM), increased glucose oxidation
in isolated soleus muscle. The nitric oxide (NO) donor, sodium
nitroprusside (SNP) (15 mM), increased glucose, pyruvate,
palmitate and leucine oxidation. Removal of extracellular Ca2+
did not affect SNP-stimulated glucose oxidation (or other
glucose utilization parameters), thus eliminating the influx of
Ca2+ as a mechanism for the increases. The guanylate cyclase
inhibitor, LY-83583 (10 WM), inhibited SNP-stimulated palmi-
tate oxidation and activation of cGMP-dependent protein kinase
(PKG). Activation of PKG might supersede any inhibitory
effects of NO on respiration to stimulate metabolic fuel
oxidation in skeletal muscle.
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1. Introduction
The neuronal (nNOS), endothelial and inducible (iNOS)
forms of nitric oxide synthase (NOS) are all found, under
di¡erent conditions, within skeletal muscle cells [1^3] and
they generate nitric oxide (NO) [4]. NOSs are located at the
sarcolemmal membrane [1] and within mitochondria [2]. NO
binds to the haem group of skeletal muscle guanylate cyclase,
increasing cyclic guanosine-3P,5P-monophosphate (cGMP) lev-
els [5]. Very few proteins or processes in skeletal muscle have
been identi¢ed as physiologically relevant targets for cGMP
dependent protein kinase (PKG) [6,7].
The current common perception is that NO inhibits respi-
ration [8], by inactivating mitochondrial enzymes, like cyto-
chrome oxidase and aconitase [8]. Much of this work has been
carried out on isolated incubated mitochondria [8]. Indeed,
few studies have monitored the e¡ects of NO on respiration
or fuel oxidation in quantitatively the most signi¢cant tissue,
skeletal muscle.
A key hypothesis is that NO is a mediator of contraction-
stimulated glucose utilization [5]. The NO donor, sodium ni-
troprusside (SNP), stimulates rates of glucose oxidation, in
association with increased rates of glucose transport and glyc-
olysis, and decreases rates of insulin-mediated glycogen syn-
thesis in isolated soleus muscle preparations [5,9]. SNP-stimu-
lated rates of glucose oxidation are inhibited by the guanylate
cyclase inhibitor LY-83583 (which also decreases the genera-
tion of cGMP by SNP; [5]). cGMP levels in soleus muscles
are also increased by inhibition of phosphodiesterase cata-
lysed cGMP hydrolysis by zaprinast (a selective inhibitor of
cGMP type V phosphodiesterase; [9,10]). Zaprinast, like NO
donors, increases glucose transport and utilization and cGMP
content in isolated incubated soleus muscle in vitro [9,10].
Furthermore, zaprinast increases the rate of glucose oxidation
[9,10]. Thus, the case for a role of cGMP in the stimulation of
skeletal muscle glucose oxidation by NO is compelling.
Activation of PKG is one possible mechanism of action of
cGMP. Alternatively, NO and/or cGMP could increase the
intracellular calcium (Ca2) concentration in skeletal muscle
via an increase in the rate of Ca2 in£ux, since NO/cGMP
regulate the activity of Ca2 channels in cells [11]. An increase
in intracellular Ca2 levels might increase rates of glucose
transport [12], glycogenolysis [13], and in particular glucose
oxidation [14], as well as decreasing insulin-mediated glycogen
synthesis [15]. Physiological increases in extra mitochondrial
Ca2 concentrations cause activation of dehydrogenases asso-
ciated with increases in both fuel oxidation and respiration
[14]. We incubated soleus muscle preparations in the presence
or absence of medium Ca2 (by adding EGTA, to chelate any
Ca2) and measured the e¡ects of SNP on glucose metabo-
lism.
The e¡ects of a cGMP analogue, 8-bromo-cGMP, on rates
of glucose oxidation were measured. The e¡ects of SNP on
the oxidation of carbohydrate (pyruvate), non-esteri¢ed fatty
acid (palmitate) and amino acid (leucine) were also deter-
mined. For palmitate oxidation, these experiments were re-
peated in the presence of the guanylate cyclase inhibitor
LY-83583, to determine the role of cGMP. Since PKG might
be important, we measured the activation of the soluble form
of PKG in soleus (type I ¢bres) and EDL (type II ¢bres)
muscles by cGMP. The e¡ects of SNP and LY-83583, either
alone or in combination, on soluble PKG activity were also
determined.
2. Materials and methods
2.1. Animals and materials
Male Wistar rats (70 and 140 g; Harlan-Olac, Bicester, Oxon., UK)
were kept in the department’s animal house under controlled condi-
tions (23 þ 1‡C; 12 h light/12 h dark cycle) and received standard
laboratory chow and water ad libitum. Food was withdrawn for 15
h before experimentation. Enzymes, chemicals, biochemicals and ra-
diochemicals were purchased from sources previously given [5,9,16^
18], except for 3-isobutyl-1-methylxanthine (IBMX), kemptide, pro-
tein kinase inhibitor (PKI), cGMP, ATP, leucine, palmitate (Sigma),
[1-14C]leucine, [1-14C]palmitate, [1-14C]pyruvate, [Q-32P]ATP (Amer-
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sham Life Science) and P81 phosphocellulose paper (Whatman Inter-
national PLC).
2.2. Incubation procedures and analysis
Rats were killed by cervical dislocation, and stripped solei prepared
as described previously [17]. Small rats (70 g) were initially sedated
with Sagatal (100 mg/kg), prior to cervical dislocation and whole EDL
and soleus muscles isolated for determination of PKG activity. The
tendons were ligated and the muscles rapidly weighed and tied at
resting length in situ on stainless steel clips, then placed in 25-ml
Erlenmeyer £asks containing 3 ml of oxygenated Krebs-Ringer bicar-
bonate bu¡er plus 10 mM HEPES (pH 7.4)/5.5 mM glucose/insulin
(10 WUnits/ml). Flasks were sealed and aerated continuously with O2/
CO2 (19:1). LY-83583 (10 WM), 8-bromo-cGMP (1 mM), pyruvate (1
mM), palmitate (0.5 mM) or leucine (1 mM) were all added to the
pre-incubation and incubation medium. After pre-incubation of
muscles for 30 min at 37‡C in an oscillating water bath (100 rev./
min), the muscles were transferred to similar medium with added
radiolabelled substrate (0.5 WCi/ml) and various compounds (e.g.
LY-83583 and/or SNP or 8-bromo-cGMP). In certain experiments,
Ca2 was omitted from the incubation medium, and 10 mM EGTA
added to chelate extracellular Ca2. The £asks were sealed and re-
gassed for the initial 15-min period in a 1-h incubation. At the end of
the incubation, muscles were blotted and rapidly frozen in liquid N2.
The incubation medium was acidi¢ed with perchloric acid (6%, w/v)
before collection of 14CO2 in plastic centre wells containing 0.2 ml of
1:1 (v/v) phenylethylamine/methanol [17]. The amount of 14CO2
formed was calculated from the speci¢c radioactivity of the extracel-
lular substrate (i.e. glucose, pyruvate, palmitate or leucine). This cal-
culation does not take into account any dilution of [14C]substrate by
endogenously available substrate. In certain experiments, the rates of
net and 14C-labelled lactate release and glycogen synthesis were de-
termined, as previously described [16]. 14C-labelled lactate is derived
only from extracellular [14C]glucose, and previous studies have shown
that the rate of 14C-labelled lactate release is a good indication of the
rate of glucose transport [16]. Muscle glycogen synthesis is measured
by the rate of [U-14C]glucose incorporation into glycogen [16^18].
For measurement of PKG, muscles were initially incubated for 110
min with constant gassing, in the presence or absence of SNP (15
mM) and/or LY-83583 (10 WM), followed by a 10-min incubation
to remove residual SNP and/or LY-83583. At the end of the second
incubation, muscles were blotted and rapidly frozen in liquid N2.
Muscle PKG activity was determined by measuring the rate of phos-
phorylation of the substrate peptide, kemptide, essentially as de-
scribed previously [19].
2.3. Statistical analysis
All results are presented as mean þ S.E.M. Student’s t-test was used
to establish the signi¢cance of di¡erences between means.
3. Results
3.1. E¡ects of SNP on soleus muscle glucose utilization in the
presence and absence of calcium, and the e¡ects of
8-bromo-cGMP on soleus muscle glucose oxidation
The e¡ects of SNP (15 mM) on rat soleus muscle glucose
utilization in the presence and absence of medium Ca2 are
given in Table 1. SNP (15 mM) signi¢cantly increased rates of
net lactate release, 14C-labelled lactate release and glucose
oxidation in the presence of medium Ca2, but signi¢cantly
decreased the rate of glycogen synthesis (Table 1). When Ca2
was removed from the medium, the rates of net lactate release,
14C-labelled lactate release and glucose oxidation all de-
creased, with no signi¢cant e¡ect on the rate of glycogen syn-
thesis (Table 1). The absence of Ca2 from the medium did
not a¡ect the stimulation of rates of net and 14C-labelled
lactate release, or the inhibition of glycogen synthesis, by
SNP (Table 1). Importantly, SNP signi¢cantly increased the
rate of glucose oxidation, in the absence or presence of Ca2
(Table 1). Percentage changes in the rates of glucose utiliza-
tion by SNP were the same either in the absence or presence
of Ca2 (Table 1). The cGMP analogue, 8-bromo-cGMP,
signi¢cantly increased the rate of soleus muscle glucose oxi-
dation (0.20 þ 0.03 vs. 0.34 þ 0.04 Wmol/h/g wet wt., for con-
trol vs. 8-bromo-cGMP (n = 11); P6 0.01).
3.2. E¡ects of SNP on pyruvate, palmitate and leucine
oxidation, and the e¡ects of LY-83583 ( þ SNP) on
palmitate oxidation
SNP (15 mM), signi¢cantly increased the rates of oxidation
of pyruvate (3.23 þ 0.26 vs. 4.24 þ 0.2 Wmol/h/g wet wt., for
control vs. SNP (n = 5); P6 0.01), palmitate (0.11 þ 0.01 vs.
0.16 þ 0.02 Wmol/h/g wet wt., for control vs. SNP (n = 5);
P6 0.05) and leucine (0.58 þ 0.03 vs. 0.79 þ 0.06 Wmol/h/g
wet wt., control vs. SNP (n = 5); P6 0.01). The magnitude
of the increase in oxidation by SNP was about the same for
all substrates (pyruvate, 32%, palmitate, 43%, and leucine,
36%). The guanylate cyclase inhibitor LY-83583 (10 WM)
alone had no signi¢cant e¡ect on palmitate oxidation (Fig.
1). Incubation of soleus muscle in the presence of both SNP
(15 mM) and LY-83583 (10 WM) caused a signi¢cant decrease
in isolated incubated soleus muscle rates of palmitate oxida-
tion, in comparison to control rates (Fig. 1).
3.3. cGMP-dependent protein kinase assay
Both soleus and EDL muscle preparations were incubated
in the absence or presence of SNP and/or LY-83583. After
incubation, PKG activities in muscle homogenate superna-
tants were determined in the absence or presence (1, 10 or
100 WM) of cGMP (Fig. 2a,b). Soleus muscles had a higher
activity of PKG compared to the activity in EDL muscle (Fig.
2a,b). Incubation of either soleus or EDL muscles with either
SNP (15 mM) or LY-83583 (10 WM) alone did not a¡ect the
activity of PKG in supernatants (Fig. 2a,b). However, incu-
FEBS 19910 5-3-98
Fig. 1. E¡ects of the NO donor, SNP (15 mM), and/or the guanyl-
ate cyclase inhibitor, LY-83583 (10 WM), on rates of oxidation of
palmitate (0.5 mM) in isolated incubated soleus muscle prepara-
tions. Results are presented as means þ S.E.M. for ¢ve separate in-
cubations. Statistically signi¢cant di¡erences between muscles incu-
bated in the absence of both SNP and LY-83583 (control)
compared with muscles incubated in the presence of SNP and/or
LY-83583 are indicated by P6 0.05 and P6 0.01.
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bation of muscle preparations with the combination of SNP
(15 mM) and LY-83583 (10 WM) caused a signi¢cant decrease
in the activity of PKG activity (both the absence and presence
of cGMP; Fig. 2a,b).
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Fig. 2. E¡ects of incubation of isolated soleus (a) and EDL (b) muscles with the NO donor, SNP (15 mM), and/or the guanylate cyclase inhib-
itor, LY-83583 (10 WM), on subsequent activity of soluble cGMP-dependent protein kinase (PKG) activity, in the absence and presence (1, 10
or 100 WM) of cGMP in muscle homogenates. Results are presented as means þ S.E.M. for four separate observations. Statistically signi¢cant
di¡erences between muscles incubated in the absence of both SNP and LY-83583 (control) compared with muscles incubated in the presence of
SNP and/or LY-83583, for the same assay cGMP concentration, are indicated by P6 0.001.
Table 1
E¡ects of the NO donor, SNP (15 mM), on rates of glucose utilization in isolated incubated soleus muscle preparations, in the presence or ab-
sence of extracellular Ca2
Incubation Rates of glucose utilization (Wmol/h/g wet wt.; n = 5)
Net lactate release 14C-Labelled lactate release Glucose oxidation Glycogen synthesis
3SNP, +Ca2 10.02 þ 1.03 5.47 þ 1.40 0.82 þ 0.06 2.23 þ 0.44
+SNP, +Ca2 20.81 þ 1.71 20.27 þ 1.73 1.91 þ 0.22 1.36 þ 0.12
3SNP, 3Ca2 3.78 þ 0.54 1.29 þ 0.80 0.31 þ 0.03 2.50 þ 0.21
+SNP, 3Ca2 9.99 þ 1.18$$$ 5.64 þ 0.59$$$ 1.69 þ 0.10$$$ 1.77 þ 0.24$
Statistically signi¢cant di¡erences between muscles incubated in the presence of Ca2 and the absence of SNP (i.e. 3SNP, +Ca2) compared with
other incubations are indicated by P6 0.05, P6 0.01 and P6 0.001. Statistically signi¢cant di¡erences between muscles incubated in the
absence of Ca2 and the absence of SNP (i.e. 3SNP, 3Ca2) compared with muscles incubated in the absence of Ca2 and the presence of SNP
(i.e. +SNP, 3Ca2) are indicated by $P6 0.05 and $$$P6 0.001.
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4. Discussion
Exercise causes marked elevations in skeletal muscle fuel
utilization, not only during, but also for many hours after
the cessation of exercise [20,21], e.g. elevated oxidative metab-
olism is sustained for 24 h after a marathon [22]. The bio-
chemical mechanism(s) responsible for increased oxidative me-
tabolism during and after exercise remain poorly understood.
The present study provides novel results that further elucidate
the roles of NO and cGMP in skeletal muscle fuel utilization
[5,9], and in particular oxidation of metabolic fuels.
NO-stimulated skeletal muscle glucose utilization and oxi-
dation is mediated, at least in part, by cGMP [5,9] (see also
Section 1). We tested the hypothesis that NO-stimulated rates
of skeletal muscle glucose utilization were mediated (either
directly, or via cGMP) through increased in£ux of extracellu-
lar Ca2. Isolated soleus muscles were incubated in the ab-
sence or presence of Ca2, with or without the nitric oxide
donor SNP. In the absence of Ca2 the rates of net- and 14C-
labelled lactate release and glucose oxidation were decreased,
with no signi¢cant e¡ect on glycogen synthesis (Table 1). SNP
(15 mM), in either the absence or presence of Ca2, markedly
increased rates of net- and 14C-labelled lactate release and
glucose oxidation, and signi¢cantly decreased glycogen syn-
thesis (Table 1). Since the magnitude of the e¡ects of SNP
is the same no matter what the conditions this suggests that
extracellular Ca2 is unimportant for stimulation of glucose
oxidation (or glucose utilization) by NO.
The increase in cGMP and the rate of glucose oxidation
caused by SNP is abolished by the guanylate cyclase inhibitor
LY-83583 [5]. In addition, 8-bromo-cGMP increased the rate
of glucose oxidation in soleus muscle in vitro (see Section 3).
All this strongly supports the proposal that cGMP plays a
vital role in one mechanism for stimulation of skeletal muscle
glucose oxidation.
Skeletal muscle can oxidise a number of substrates, includ-
ing fatty acids and amino acids. In the present study, SNP
stimulated the rates of oxidation of pyruvate, palmitate and
leucine in soleus muscles in vitro (see Section 3). The magni-
tude of stimulation by SNP was similar for all rates of sub-
strate oxidation (i.e. 32%, 43% and 36% increases for rates of
pyruvate, palmitate and leucine oxidation, respectively). SNP
(15 mM) signi¢cantly increased rates of glucose oxidation by
133% (Table 1). The guanylate cyclase inhibitor LY-83583 (10
WM) alone had no e¡ect on rates of palmitate oxidation (Fig.
1). However, LY-83583 inhibited SNP-stimulated rates of pal-
mitate oxidation, to a value lower than control rates (Fig. 1).
This is further evidence that NO-stimulated rates of skeletal
muscle substrate oxidation are via cGMP since LY-83583
would inhibit guanylate cyclase activation by NO, thus pre-
venting a rise in cGMP levels.
Septic shock, via cytokine production, causes increased ex-
pression iNOS in muscle [3]. iNOS expression is induced in
cultured muscle cells by cytokines, and this is associated with
increased rates of glucose transport [23]. Whether increased
rates of leucine oxidation observed during sepsis [24] are
mediated through increased NO generation in skeletal muscle
(as observed in vitro in the present study) remains to be de-
termined.
Activation of PKG may, at least in part, regulate fuel ox-
idation in skeletal muscle. Soleus contains more soluble PKG
activity than EDL (Fig. 2a,b). Incubation of soleus or EDL
muscle preparations with either SNP (15 mM) or LY-83583
(10 WM) did not a¡ect soluble PKG activities (Fig. 2a,b).
However, a combination of SNP (15 mM) and LY-83583
(10 WM) signi¢cantly decreased soluble PKG activity (in
both the absence and presence of cGMP in the enzyme assay;
Fig. 2a,b). These results suggest that an e¡ect of NO on skel-
etal muscle with a low cGMP content (due to inhibition of
guanylate cyclase by LY-83583) was marked inhibition of
soluble PKG. Thus, cGMP appears to protect soluble PKG
from inhibition by NO. Incubation of soleus muscles with
both SNP (15 mM) and LY-83583 (10 WM) also decreased
palmitate oxidation (Fig. 1) suggesting that a mechanism op-
erates in the cell in which activation of PKG promotes skel-
etal muscle fuel oxidation.
This is the ¢rst study to provide evidence for a role for
activation of soluble PKG, by cGMP, in the stimulation of
oxidative metabolism in skeletal muscle. Glucose oxidation is
activated by NO in smooth muscle [25]. NO increases rates of
oxidation of glucose, pyruvate, palmitate and leucine (see Sec-
tion 3), suggesting activation of a common mechanism for
oxidation of all these substrates. Whilst a number of potential
mechanisms exist, we suggest that mitochondrially located
uncoupling protein-3 (UCP-3), which is highly expressed in
skeletal muscle [26], becomes phosphorylated and activated
by PKG. Uncoupling of respiration, through activation of
UCP-3, would increase oxidative metabolism in mitochondria
[27]. UCP-3 has a potential PKG phosphorylation site (not
found in UCP-1 and UCP-2). The potential phosphorylation
site (serine-160) has arginine and lysine residues upstream,
characteristic of a PKG phosphorylation site [7], and is lo-
cated in the middle of a hydrophilic region of UCP-3, suggest-
ing it should be accessible to phosphorylation [26]. Whether
this site is indeed phosphorylated by PKG in vivo, or whether
such a phosphorylation would a¡ect UCP-3 function, requires
further work. Clearly much more research is required before
the understanding of the NO/cGMP/PKG system in skeletal
muscle fuel utilization is complete.
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